PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.

Authors

Gabriele Madonna
Carmen Ballesteros-Merino, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA.Follow
Zipei Feng, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Cancer Biology, Oregon Health & Science University, Portland, OR, USA.Follow
Carlo Bifulco, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Pathology, Providence Portland Medical Center, Portland, OR, USA.Follow
Mariaelena Capone
Diana Giannarelli
Domenico Mallardo
Ester Simeone
Antonio M Grimaldi
Corrado Caracò
Gerardo Botti
Bernard A Fox, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.Follow
Paolo A Ascierto

Document Type

Article

Publication Date

1-1-2018

Publication Title

Oncoimmunology

Keywords

Immunotherapy; Ipilimumab; Melanoma; PD-L1; Tumor microenvironment; genomics

Clinical Institute

Cancer

Department

Earle A. Chiles Research Institute

Department

Oncology

Recommended Citation

Madonna, Gabriele; Ballesteros-Merino, Carmen; Feng, Zipei; Bifulco, Carlo; Capone, Mariaelena; Giannarelli, Diana; Mallardo, Domenico; Simeone, Ester; Grimaldi, Antonio M; Caracò, Corrado; Botti, Gerardo; Fox, Bernard A; and Ascierto, Paolo A, "PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab." (2018). Articles, Abstracts, and Reports. 915.
https://digitalcommons.providence.org/publications/915